Abzena is the leading end-to-end CDMO + CRO for bioconjugates (ADCs, AOCs, & RDCs) and complex biologics (antibodies, bi/multispecifics, fusion proteins). From discovery through commercial launch, it supports customers with fully integrated programs or individual services designed to de-risk and streamline the design, development, and GMP manufacture of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena implements innovative solutions that enable biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK. Learn more at abzena.com.
